Clinical Trials

46 enrolled

Osteosarcoma

NCT03742193 2023-11-01

PROACH

43 enrolled

Osteosarcoma

NCT04267549 2023-07-06

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04930315 2023-06-13

CAPT

78 enrolled

Carcinoma, Hepatocellular

NCT05853172 2023-05-10

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Stomach Neoplasms

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Nasopharyngeal Carcinoma

NCT04609176 2023-04-21

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

64 enrolled

Stomach Neoplasms

NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

50 enrolled

Cholangiocarcinoma

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05597527 2022-10-28

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

35 enrolled

Ovarian Neoplasms

NCT04012827 2022-09-07

Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

108 enrolled

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

42 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT04878107 2022-05-02

SABRE

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

68 enrolled

Metastatic Gastric Adenocarcinoma

NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

31 enrolled

Stomach Neoplasms

NCT05265793 2022-03-04

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

45 enrolled

Carcinoma, Carcinosarcoma

NCT03801200 2022-02-08

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

90 enrolled

CNS

Brain Neoplasms

NCT05225844 2022-02-07

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

150 enrolled

Gastrointestinal Neoplasms

NCT05171309 2021-12-28

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

35 enrolled

Carcinoma, Hepatocellular

NCT04901754 2021-12-08

CAMERA

38 enrolled

Small Cell Lung Carcinoma

NCT05095636 2021-10-27

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

102 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

172 enrolled

Uterine Cervical Neoplasms

NCT04006821 2021-09-30

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Stomach Neoplasms

NCT04724226 2021-09-05

C-couple

34 enrolled

Carcinoma, Hepatocellular

NCT04934618 2021-06-22

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

85 enrolled

Stomach Neoplasms

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

35 enrolled

Metastatic Gastric Adenocarcinoma

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

20 enrolled

Other solid neoplasm

Solid Tumor

NCT04068974 2021-03-16

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

28 enrolled

Ovarian Neoplasms

NCT04792515 2021-03-11

CCWSA/OAFLAG

67 enrolled

Locally Advanced Gastric Cancer

NCT04440917 2021-02-02

IMplus

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04683198 2020-12-24

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

69 enrolled

Small Cell Lung Carcinoma

NCT03154983 2020-12-09

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

48 enrolled

Stomach Neoplasms

NCT04612894 2020-11-03

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

31 enrolled

Thyroid Neoplasms

NCT04588987 2020-10-19

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

CNS

Glioma

NCT04590625 2020-10-19

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

58 enrolled

Ovarian Neoplasms

NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Other solid neoplasm

Solid Tumor

NCT04547088 2020-09-14

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

27 enrolled

Nasopharyngeal Carcinoma

NCT04548271 2020-09-14

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT04506242 2020-09-09

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

74 enrolled

NSCLC

NCT03267654 2020-08-03

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03758677 2020-07-23

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Carcinoma, Non-Small-Cell Lung

NCT03389087 2020-07-10

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

Small Cell Lung Carcinoma

NCT04453930 2020-07-01

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）